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The influenza virus PB1-F2 is an 87-amino acid mitochondrial protein that previously has been shown to induce cell
death, although the mechanism of apoptosis induction has remained unclear. In the process of characterizing its
mechanism of action we found that the viral PB1-F2 protein sensitizes cells to apoptotic stimuli such as tumor necrosis
factor alpha, as demonstrated by increased cleavage of caspase 3 substrates in PB1-F2-expressing cells. Moreover,
treatment of purified mouse liver mitochondria with recombinant PB1-F2 protein resulted in cytochrome c release, loss
of the mitochondrial membrane potential, and enhancement of tBid-induced mitochondrial permeabilization,
suggesting a possible mechanism for the observed cellular sensitization to apoptosis. Using glutathione-S-transferase
pulldowns with subsequent mass spectrometric analysis, we identified the mitochondrial interactors of the PB1-F2
protein and showed that the viral protein uniquely interacts with the inner mitochondrial membrane adenine
nucleotide translocator 3 and the outer mitochondrial membrane voltage-dependent anion channel 1, both of which
are implicated in the mitochondrial permeability transition during apoptosis. Consistent with this interaction, blockers
of the permeability transition pore complex (PTPC) inhibited PB1-F2-induced mitochondrial permeabilization. Based on
our findings, we propose a model whereby the proapoptotic PB1-F2 protein acts through the mitochondrial PTPC and
may play a role in the down-regulation of the host immune response to infection.
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Introduction
Inﬂuenza virus infection results in the activation of cellular
pathways aimed at inhibition of viral replication and
induction of an antiviral state [1]. To overcome the antiviral
signaling, inﬂuenza viruses evolved accessory proteins, such as
NS1 and PB1-F2, that have been proposed to down-modulate
different aspects of the host immune response [2,3]. While the
NS1 protein has been shown to play a role in the inhibition of
the type I interferon response, the function of the PB1-F2
protein remains elusive.
PB1-F2 is a novel 87-amino acid protein serendipitously
identiﬁed in an alternate reading frame of the PB1 gene of
the inﬂuenza A/PR/8/34 virus [3]. Initial studies revealed that
the protein localizes to mitochondria resulting in the
alteration of mitochondrial morphology, dissipation of
mitochondrial membrane potential, and cell death, which
was more pronounced in cells of immune origin [3]. The basic
amphipathic helix in the C-terminal region of the PB1-F2
protein was subsequently determined to be responsible for its
mitochondrial localization [4,5]. Synthetic peptides derived
from the C-terminal domain of the protein were shown to
have an ability to oligomerize and nonspeciﬁcally permeabi-
lize lipid bilayer membranes [6,7], properties observed with
some known cellular mitochondrial apoptotic mediators [8,9].
Despite these ﬁndings, however, the precise mechanism and
function of PB1-F2-induced apoptosis remains unclear.
Regulation of the mitochondrial permeabilization has been
implicated in the life cycle of several known human
pathogens [10,11]. Indeed, stable cell lines overexpressing
the antiapoptotic proteins of the Bcl-2 family are less
permissive to inﬂuenza viral replication than their parental
cell lines [12–14], highlighting the importance of the role of
the mitochondrial apoptotic pathways in inﬂuenza virus
pathogenesis.
Cellular apoptotic signaling to mitochondria proceeds
through activation of the members of the proapoptotic Bcl-
2 family BH3-only proteins such as Bid, which exert their
effects through induction of the release of several mitochon-
drial apoptotic mediators, such as cytochrome c, apoptosis-
inducing factor, endonuclease G, Smac/Diablo, and Omi/
HtrA2 [15]. The exact mechanism leading to the mitochon-
drial permeabilization is still under investigation, but is
known to involve cellular apoptotic mediators of the Bcl-2
family, such as Bak and Bax, and proteins constituting the
permeability transition pore complex (PTPC), such as the
adenine nucleotide translocator 3 (ANT3) in the inner
mitochondrial membrane and the voltage-dependent anion
channel 1 (VDAC1) in the outer mitochondrial membrane
[16–19].
In view of the possible contribution of the PB1-F2 protein
to inﬂuenza viral pathogenesis, we sought to determine the
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and to further elucidate its mechanism of action. We show
that the mitochondrial permeabilization by the PB1-F2
protein renders cells sensitive to the proapoptotic effect of
tumor necrosis factor alpha (TNFa) through tBid signaling.
Furthermore, our results indicate that PB1-F2-induced
apoptosis proceeds through a unique mechanism involving
its interaction with the ANT3 and VDAC1 proteins of the
PTPC at the inner and outer mitochondrial membranes,
respectively. With the use of ANT3-speciﬁc inhibitor, we
conclude that PB1-F2 directly permeabilizes mitochondria in
an ANT3-dependent manner. The results of our studies
provide a deeper insight into the function of the PB1-F2
protein and underscore the role of the PTPC in mitochon-
drial permeabilization and cell death in inﬂuenza virus-
infected cells.
Results
PB1-F2 Protein Sensitizes Transfected Cells to Apoptotic
Stimuli
We investigated whether transient expression of the
inﬂuenza virus PB1-F2 protein would enhance cell death by
intrinsic and extrinsic proapoptotic stimuli (Figure 1). To
achieve maximal transient transfection efﬁciency of the PB1-
F2 protein, the proapoptotic effect of the agents was initially
assayed in PB1-F2-transfected 293T cells, where apoptosis was
detected by cleavage of poly A ribose polymerase (PARP), a
direct substrate of caspase 3 (Figure 1A). The unrelated
inﬂuenza virus protein, nucleoprotein (NP), which does not
induce apoptosis, was used as a control. Reduction of full-
length PARP with a concomitant increase in cleaved PARP
product was seen in PB1-F2-transfected cells in response to
DNA damage caused by UV irradiation and cisplatin, when
compared to the control (Figure 1A). Treatment of PB1-F2-
transfected cells with 50 ng/ml of TNFa or with 5 ng/ml of
TNF-related apoptosis-inducing ligand resulted in signiﬁcant
increase in PARP cleavage, as compared to the control
(Figure 1A). In view of the ﬁndings that PB1-F2 sensitized
cells to both extrinsic and intrinsic apoptotic stimuli, we
tested whether the PB1-F2-expressing cells are also sensitized
to death due to detachment from the growth matrix (anoikis).
The activation of anoikis has also been shown to involve
proapoptotic members of the BH3 family [20,21]. Indeed,
PB1-F2 also sensitized cells to death by anoikis, as demon-
strated by rapid membrane blebbing and fragmentation of
trypsinized human lung epithelial A549 cells transfected with
a construct expressing PB1-F2 (Figure 1B) [22]. To determine
whether the PB1-F2-expressing cells were indeed undergoing
apoptosis, we labeled PB1-F2-transfected A549 cells with M30
antibody to caspase-cleaved cytokeratin. Interestingly, in the
absence of other apoptotic stimuli, only a small proportion of
PB1-F2-expressing cells underwent apoptosis (Figure 1C),
which could explain the relatively low proapoptotic effect of
the PB1-F2 protein observed in the assays above. Overall,
these results suggest that the PB1-F2 protein enhances the
effect of cellular proapoptotic stimuli.
Sensitization to Apoptosis by the PB1-F2 Protein Is
Inhibited by Bcl-xL
Since PB1-F2 has been shown to localize to mitochondria
[3,4], we investigated whether mitochondrial apoptotic
mechanisms are involved in PB1-F2-induced apoptotic
enhancement. Mitochondrial permeabilization by cellular
apoptotic mediators is controlled by the antiapoptotic
proteins such as Bcl-xL and Bcl-2. Given the dependence of
PB1-F2-induced apoptosis on cellular apoptotic factors, we
decided to determine whether PB1-F2-induced apoptotic
sensitization can overcome the cytoprotective effect of Bcl-
xL. For the purposes of our experiments, we used A549 cells
to generate a cell line stably overexpressing Bcl-xL protein
(A549-Bcl-xL) and a respective control cell line expressing the
gene encoding neomycin resistance. The resulting cell lines
both exhibited transient transfection efﬁciencies of around
60% as witnessed by transient expression of green ﬂuorescent
protein (GFP; unpublished data).
In a control cell line stably transfected with neomycin
vector (A549-neo), expression of PB1-F2 enhanced the
proapoptotic effect of TNFa, as demonstrated by immuno-
labeling with M30 antibody speciﬁc for cleaved cytokeratin 18
(Figure 2A). Coimmunostaining for PB1-F2 revealed that the
PB1-F2-expressing cells were indeed undergoing apoptosis.
However, PB1-F2-induced apoptosis in response to TNFa was
inhibited in the A549 cell line stably overexpressing Bcl-xL
(Figure 2B). Overall these results suggest that the mitochon-
drial apoptotic pathways are required for PB1-F2-mediated
apoptotic enhancement.
The Influenza Virus PB1-F2 Protein Disrupts Mitochondrial
Organization and Induces the Release of Cytochrome C
To further characterize PB1-F2-mediated apoptotic en-
hancement, we generated a monoclonal antibody (26D3)
speciﬁc for the N-terminal domain of the protein, and
conﬁrmed by microscopy that the PB1-F2 protein expressed
from transfected plasmid localized to mitochondria in
A549-neo and A549-Bcl-xL cells (Figure 3A). While in
normal cells mitochondria are usually distributed along
the microtubular networks, mitochondria of PB1-F2-trans-
fected cells lost the normal tubuloreticular organization and
displayed a punctiform appearance (Figure 3A). Interest-
ingly, this effect was not inhibited by Bcl-xL overexpression
(Figure 3A), suggesting that disruption of the mitochondrial
network is not the primary mechanism for PB1-F2-induced
apoptosis.
To further evaluate the effect of PB1-F2 protein on the
mitochondrial apoptotic pathways, we analyzed the PB1-F2-
expressing cells for release of cytochrome c from the
mitochondria. HeLa cells were transfected with hemaggluti-
nin (HA)-tagged PB1-F2, treated with 50 ng/ml TNFa for 8 h,
and stained for HA tag and cytochrome c. Expression of the
PLoS Pathogens | www.plospathogens.org September 2005 | Volume 1 | Issue 1 | e4 0041
Influenza Virus PB1-F2 Induces Apoptosis
Synopsis
PB1-F2 is a short polypeptide encoded by influenza viruses. While
the role of this viral protein is not completely understood, it is
known to localize in the mitochodria of the infected cell and to
promote cell death. The authors found that PB1-F2 sensitizes cells to
death through interactions with two mitochondrial proteins, ANT3
and VDAC1. These interactions promote the permeabilization of the
mitochodria and facilitate the release of mitochondrial products that
trigger cell death (apoptosis). PB1-F2-mediated cell death through
the mitochondria is likely to contribute to the pathogenicity of the
influenza virus.PB1-F2 protein resulted in the release of cytochrome c from
mitochondria (Figure 3B) in a subset of cells, as witnessed by
diffusion of cytochrome c in the cytoplasm. For a better
quantitative measure of the amount of cytochrome c released,
293T cells were transfected with a plasmid expressing PB1-F2
or an empty vector and 24 h later were treated for 8 h with 50
ng/ml TNFa. The cells were subsequently fractionated into
cytosolic and mitochondrial fractions, and the amount of
cytochrome c remaining in the mitochondrial fraction was
determined by Western blot (Figure 3C). Treatment of the
PB1-F2 transfected cells with TNFa resulted in enhanced
r e l e a s eo fc y t o c h r o m ecf r o mt h em i t o c h o n d r i aw h e n
compared to the vector control.
PB1-F2 Directly Induces Mitochondrial Permeabilization
and Sensitizes Mitochondria to the Proapoptotic Effect of
tBid
To further investigate whether the effect of PB1-F2 protein
on the mitochondria is direct, we incubated puriﬁed mouse
liver mitochondria with recombinant PB1-F2 protein. Re-
combinant tBid protein was used as a control. Treatment of
mitochondria with the PB1-F2 protein resulted in the release
of cytochrome c, which increased at higher concentrations,
suggesting a direct role for PB1-F2 in promoting mitochon-
drial outer membrane permeabilization (Figure 4A). This
effect was not observed when a recombinant glutathione-S-
Figure 1. PB1-F2 Protein Sensitizes Cells to Apoptosis in Response to Cytotoxic Stimuli
(A) Expression of PB1-F2 protein enhanced cleavage of poly-A ribose polymerase (PARP) in response to cytotoxic agents. 293T cells were transfected
with either PB1-F2 (F2) or influenza virus NP (NP) for 24 h and were subsequently treated for 6 h with 50 ng/ml TNFa, 5 ng/ml TNF-related apoptosis-
inducing ligand, 100 lM cisplatin, or UV-irradiation at 60 J/m
2 as indicated. All cells were collected 6 h later, lysed, and processed by immunoblotting for
cleaved PARP.
(B) PB1-F2 protein predisposes cells to death by anoikis. A549 cells were transfected either with empty vector or with PB1-F2 and trypsinized 24 h post-
transfection. Cells were incubated in PBS with 0.3% BSA for 15 min, pipetted onto microscope slides, and changes in cell morphology (membrane
blebbing indicated by arrows) were visualized by phase-contrast microscopy [22].
(C) A subset of PB1-F2-expressing cells undergoes apoptosis. A549 cells were transfected with HA-tagged PB1-F2 for 24 h and stained for HA epitope
and cleaved cytokeratin (M30).
DOI: 10.1371/journal.ppat.0010004.g001
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Influenza Virus PB1-F2 Induces Apoptosistransferase (GST) protein was used in this assay at similar
concentrations (unpublished data). In view of the previous
report that the C-terminal region of PB1-F2 protein targets it
to the inner mitochondrial membrane, we proceeded to
investigate whether PB1-F2-induced mitochondrial permea-
bilization also involves the inner mitochondrial membrane.
Forthispurposeweusedthemitochondrialpotential-sensitive
dye JC-1 to determine whether incubation of puriﬁed
mitochondria with recombinant PB1-F2 protein would result
indissipationofthemitochondrialinnermembranepotential.
The uptake of the JC-1 dye by intact mitochondria results in
increased red-orange ﬂuorescence at 590 nm upon excitation
at 490 nm. As can be seen from Figure 4B, incubation of the
puriﬁed mitochondria for 10 min with increasing doses of
PB1-F2 resulted in reduction of JC-1 ﬂuorescence at 590 nm,
suggesting that the PB1-F2 protein-induced mitochondrial
permeabilizationinvolvestheinnermitochondrialmembrane.
Interestingly, while recombinant PB1-F2 protein was, at
equimolar concentrations, less effective than tBid in releasing
cytochrome c (Figure 4A), it was comparable to tBid in
permeabilization of the inner mitochondrial membrane. This
suggests that while loss in the mitochondrial membrane
potential might not be required for tBid-induced cytochrome
c release [23], it may be necessary for PB1-F2-induced
mitochondrial permeabilization. These results conﬁrmed
previous ﬁndings that showed that expression of PB1-F2
protein in cells can lead to dissipation of the mitochondrial
membrane potential [3]. Interestingly, as we and others
showed, expression of the PB1-F2 protein itself does not cause
signiﬁcant levels of apoptosis [3]. This suggests that the inner
membrane permeabilization by the PB1-F2 protein might not
be the primary mechanism of apoptosis induction. Rather, we
Figure 2. PB1-F2 Protein-Mediated Enhancement of TNFa-Induced Apoptosis Is Inhibited by Bcl-xL
A549 cells containing a stably-integrated neomycin resistance gene (A549-neo) (A), or A549 cells stably overexpressing Bcl-xL (A549-Bcl-xL) (B) were
transfected with either empty vector or vector encoding HA-tagged PB1-F2. At 24 h post-transfection, cells were treated with 50 ng/ml TNFa, where
indicated. Then 6 h post-treatment, the cells were fixed and stained with M30 antibody to cleaved cytokeratin and with anti-HA antibody.
DOI: 10.1371/journal.ppat.0010004.g002
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lization acting in conjunction with another apoptotic mech-
anism may be responsible for PB1-F2-mediated apoptotic
enhancement illustrated in Figures 1 and 2.
In view of the fact that both intrinsic and extrinsic cellular
apoptotic stimuli converge on the mitochondria through
signaling of the Bcl-2 family BH3 proteins, we investigated
whether the presence of PB1-F2 in suboptimal concentra-
tions would enhance the release of cytochrome c from
puriﬁed mitochondria by recombinant tBid. Incubation of
the puriﬁed mitochondria with recombinant tBid results in
release of cytochrome c at tBid concentrations as low as 10
nM (Figure 4C). Preincubation of the puriﬁed mitochondria
with 10 nM PB1-F2 augments the tBid-induced cytochrome c
release by a factor of almost ten (Figure 4C). As the PB1-F2
protein was used at a concentration at which it fails to release
cytochrome c by itself, the result suggests that the effect of
PB1-F2 and tBid is not simply additive. We speculate that
PB1-F2-induced permeabilization of the inner mitochondrial
membrane may augment cytochrome c release in response to
Figure 3. Influenza Virus PB1-F2 Protein Disrupts Mitochondria
(A) PB1-F2 disrupts reticulotubular mitochondrial organization. A549-neo and A549-Bcl-xL cells were transfected with HA-tagged PB1-F2 for 24 h and
stained with antibody against HA tag and with human anti-mitochondrial serum as a marker for mitochondria. The cells with punctiform mitochondria
are indicated by (*), while the cells with normal reticulotubular mitochondrial organization are indicated by (#).
(B) PB1-F2 protein induces release of mitochondrial cytochrome c in transfected cells. HeLa cells were transfected with HA-tagged PB1-F2 for 24 h,
treated with 50 ng/ml TNFa for 8 h, and stained with anti-HA antibody (green, secondary antibody FITC), anti-cytochrome c antibody (red, secondary
antibody Alexa 568), and DAPI (blue). The cells were visualized by confocal microscopy.
(C) Subcellular fractionation of 293T cells transfected with PB1-F2. 293T cells were transfected for 24 h and subsequently were either mock-treated or
treated with 50 ng/ml TNFa. Cells were subsequently collected and fractionated into the cytosolic and mitochondrial fractions. The amount of
cytochrome c remaining in the mitochondrial fraction was detected by Western blot. Tom20 protein was used as a loading control.
DOI: 10.1371/journal.ppat.0010004.g003
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apoptosis by the PB1-F2 may proceed through its potentia-
tion of the effects of the cellular BH3 family proteins.
Previous studies revealed that the PB1-F2 protein localizes
to both inner and outer mitochondrial membranes [3–5]. As
the cellular apoptotic proteins were previously shown to act
through the mitochondrial proteins controlling permeabili-
zation of the inner as well as outer mitochondrial mem-
branes, we speculate that the observed PB1-F2-induced
apoptotic sensitization could proceed via components in
both membranes. To investigate possible involvement of
mitochondrial proteins in PB1-F2-induced apoptosis, we
sought to identify potential mitochondrial interactors of
the PB1-F2 protein.
The PB1-F2 Protein Interacts with ANT3 and VDAC1
Proteins of the Mitochondrial PTPC
PB1-F2 protein was expressed in 293T cells as an N-
terminal GST fusion protein, and the complexes between
GST-PB1-F2 and its interacting proteins were pulled down
with glutathione-Sepharose beads. Proteins were subse-
quently eluted from the beads, separated by SDS gel electro-
phoresis, and visualized by silver stain. An unrelated
polypeptide of similar length fused to GST (GST-Nipah-Wc,
containing the last 43 amino acids of the W protein of the
Nipah virus fused to GST) was used as a control. Unique
protein bands at approximately 36, 55, and 80 kDa speciﬁc
for the PB1-F2 fusion protein but not GST or the control
protein were detected (Figure 5A, lanes 4 and 5). Mass
spectrometry analysis of the proteins identiﬁed the 36-kDa
band as the mitochondrial ANT3, the 55-kDa band as beta
tubulin, and the 80-kDa band as cytokeratin. The latter was
likely a contaminant of the protein preparation. While
interaction of PB1-F2 with tubulin may be important for
PB1-F2-induced mitochondrial disorganization (see Figure
3A), we chose to focus on the ANT3 protein, which is known
to be involved in mitochondrial apoptosis. Coimmunopreci-
pitation experiments with transfected HA-tagged ANT3
conﬁrmed the interaction between PB1-F2 and ANT3 (Figure
5B). As expected, transfected HA-tagged ANT3 localized to
the mitochodria (Figure 5C).
To verify that the interaction between PB1-F2 and ANT3
was direct, we expressed
35S-labeled ANT3 in vitro and
performed GST pulldowns on the labeled protein with either
GST or GST-PB1-F2 proteins. Only GST-PB1-F2 was able to
coprecipitate the in vitro-translated ANT3 protein, suggest-
ing that direct interaction between PB1-F2 and ANT3 is likely
(Figure 5D).
Previous studies revealed that the predicted basic amphi-
pathic helix formed by amino acids 69–82 is sufﬁcient for
targeting PB1-F2 to the inner mitochondrial membrane [4].
However, immunoelectron microscopy studies had also
previously shown that the full-length PB1-F2 protein localized
to both inner and outer mitochondrial membranes [3],
suggesting that the N terminus of the protein may play a role
in targeting the protein to the outer mitochondrial mem-
brane. Thus, while ANT3 was the only component of the PTPC
identiﬁed by mass spectrometry to interact with PB1-F2, we
could not exclude the possibility that PB1-F2 exerts its effect
in conjunction with other proteins of the pore complex. Since
ANT3 is exclusively an inner membrane protein, we specu-
lated that the outer membrane PB1-F2 may be acting through
Figure 4. Influenza Virus PB1-F2 Protein Directly Permeabilizes
Mitochondria
(A) Recombinant PB1-F2 protein caused release of cytochrome c from
purified mouse mitochondria. Mouse mitochondria (50 lg total protein)
were incubated for 1 h at 30 8C with recombinant protein of interest at
indicated concentrations. The amount of cytochrome c released in the
supernatant was assayed by immunoblotting using anti-cytochrome c
antibody. Recombinant tBid protein was used as a control. The
mitochondrial pellet was assayed for the Tom20 protein to ensure an
equal amount of mitochondria was used.
(B) PB1-F2 and tBid cause dissipation of the mitochondrial membrane
potential. Mouse mitochondria (50 lg) were incubated for 10 min at 30
8C with the protein of interest at indicated concentrations. Relative loss
in membrane potential was measured by uptake of membrane potential-
sensitive JC-1 dye. Data is presented as percent fluorescence relative to
mock-treated mitochondria.
(C) PB1-F2 protein enhances tBid-induced cytochrome c release. Purified
mouse mitochondria (50 lg) were incubated with 10 nM PB1-F2 or
mock-treated for 15 min in 20 ll and were subsequently treated with
recombinant tBid in the indicated concentrations for 1 h in a total
volume of 30 ll. The supernatants were assayed for cytochrome c release
by Western blot. The mitochondrial pellet was processed for Tom20 to
ensure equal amount of mitochondria used.
DOI: 10.1371/journal.ppat.0010004.g004
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periments revealed that PB1-F2 protein also interacted with
VDAC1 (Figure 5B), and GST pulldown experiments with in
vitro-translated VDAC1 conﬁrmed that the interaction is
likely direct (Figure 5D). These ﬁndings were surprising, since
VDAC1 protein was not identiﬁed in the original experiment
by mass spectrometry. While it is likely that the VDAC1
protein was missed in our analysis, it is also possible that the
N-terminal GST tag may have prevented the interaction of the
PB1-F2 protein with VDAC1 within the cell.
ANT3 and VDAC1 appear to be critical components of
the pore complex [19]. ANT3 is an inner mitochondrial
membrane protein that functions as an antiporter catalyz-
ing the exchange of ATP for ADP [19,24]. In the presence of
Figure 5. PB1-F2 Protein Interacts with ANT3 and VDAC1
(A) Cellular proteins pulled down with GST-PB1-F2 were separated by 12% SDS-PAGE and silver-stained. The asterisks mark the protein bands that are
unique to the GST-PB1-F2 lanes (;36 kDa, 55 kDa, and 80 kDa). Lanes 4 and 5 represent the results of two separate pulldown experiments.
(B) PB1-F2 specifically interacts with ANT3 and VDAC1 but not other outer and inner mitochondrial membrane proteins. Interaction of PB1-F2 with ANT3
and VDAC1 was confirmed in 293T cells by coimmunoprecipitation with transfected HA-tagged ANT3 and flag-tagged VDAC1 (top five images). Tom20,
COXIV, and TIM 44 proteins were used as the mitochondrial coimmunoprecipitation controls.
(C) Transfected ANT3 and VDAC1 localize to mitochondria. 293T cells were transfected with Flag-tagged ANT3 and VDAC1 for 24 h and were
subsequently fractionated to generate the cytosolic and mitochondrial fractions. Tom20 protein served as a control for the mitochondrial fraction. Each
sample was processed in triplicate (lanes 1, 2, and 3, ANT3; lanes 4, 5, and 6, VDAC1).
(D) PB1-F2 directly interacts with ANT3 and VDAC1.
35S-labeled ANT3 and VDAC1 were expressed in vitro using a rabbit reticulocyte lysate system and
subjected to pulldown with either 5 lg GST (left lane) or GST-PB1-F2 (right lane). Proteins were separated by 12% SDS-PAGE and visualized by
autoradiography.
(E) PB1-F2 expressed during viral infection interacts with ANT3 and VDAC1. 293T cells were transfected with Flag-tagged ANT3 and VDAC1 proteins and
24 h later were infected with wild-type PR8 virus (PR8) or the virus knocked out for PB1-F2 expression (del) at an MOI of 2. 15 h after infection, the cells
were collected and the immunoprecipitation with anti-PB1-F2 polyclonal serum was performed. Influenza virus NP was used as a control to show equal
levels of infection between the samples. WB, Western blot.
DOI: 10.1371/journal.ppat.0010004.g005
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conformational changes resulting in the formation of
nonspeciﬁc pores in the inner mitochondrial membrane.
Apoptotic stimuli also trigger conformational changes in
the outer membrane protein VDAC1, which forms pores in
the outer mitochondrial membrane. ANT3 and VDAC1 are
believed to interact, forming the PTPC, which leads to
dissipation of the inner mitochondrial membrane potential
and the release of apoptotic mediators from the mitochon-
drial intermembrane space [24–26].
To eliminate the possibility of nonspeciﬁc interaction of
PB1-F2 with mitochondrial proteins, we performed PB1-F2
coimmunoprecipitation experiments with the outer mito-
chondrial membrane transport protein Tom20, the inner
mitochondrial membrane protein COXIV, and the protein
Tim44, which localizes to the matrix side of the inner
mitochondrial membrane (Figure 5B). PB1-F2 protein failed
to coimmunoprecipitate with any of these proteins, further
conﬁrming the speciﬁcity of its interaction with ANT3 and
VDAC1 (Figure 5B).
To conﬁrm that the transfected tagged ANT3 and VDAC1
proteins were properly targeted to the mitochondria, we
performed subcellular fractionation and determined that the
majority of the expressed ANT3 and VDAC1 are indeed
present within the mitochondrial fraction (Figure 5C).
Furthermore, to determine whether PB1-F2 interacts with
ANT3 and VDAC1 within the context of viral infection, we
infected Flag-ANT3- and Flag-VDAC1-transfected 293T cells
with either a wild-type PR8 virus or with its correspondent
virus knocked out for PB1-F2 protein expression. Immuno-
precipitation experiments with anti-PB1-F2 polyclonal serum
revealed that the PB1-F2 protein interacts with ANT3 and
VDAC1 during the viral infection (Figure 5E).
Due to lack of availability of good antibodies speciﬁc for
ANT3 and VDAC1, we were unable to demonstrate the
interaction of PB1-F2 with the endogenous proteins, apart
from the interaction shown by mass spectrometry. Thus, to
further conﬁrm the speciﬁcity of the interaction, we
proceeded to identify the interaction domains within the
PB1-F2 protein.
The C-Terminal Domain of PB1-F2 Protein Is Responsible
for the Interaction with ANT3, While Both C- and N-
Terminal Domains Interact with VDAC1
Expression of HA-tagged N- or C-terminal domains of PB1-
F2 was unsuccessful and resulted in fragments which
appeared to be unstable (unpublished data). To stabilize each
part of the protein, we generated HA-tagged GFP-fusion
protein constructs of each domain (HA-nF2-GFP and HA-
cF2-GFP; Figure 6A). The N-terminal region (HA-nF2-GFP)
included amino acids 1–38, while the C-terminal fusion
protein (HA-cF2-GFP) included amino acids 39–87 (Figure
6A). In transfected HeLa cells, full-length HA-PB1-F2-GFP
fusion protein and HA-cF2-GFP protein localized to the
mitochondria, while the HA-nF2-GFP fusion protein was
diffusely distributed in the cytoplasm and the nucleus (Figure
6B). Since possible interaction of the N terminus of the
protein with its cellular target could be inﬂuenced by its
subcellular localization, we generated an additional construct
fusing the N terminus to the mitochondrial targeting signal of
the cytochrome oxidase, which targets the protein to the
inner mitochondrial membrane (HA-MTS-nF2-GFP) [27]. The
resultant fusion protein localized to mitochondria (Figure
6B). We next determined whether the fusion proteins
interacted with Flag-tagged ANT3 and VDAC1 in transfected
293T cells. Both HA-PB1-F2-GFP and HA-cF2-GFP fusion
proteins proved to interact with both VDAC1 and ANT3,
while the HA-nF2-GFP interacted only with VDAC1 (Figure
6C and 6D). HA-MTS-nF2-GFP protein possessing the inner
mitochondrial membrane targeting sequence still failed to
interact with ANT3, conﬁrming that the N terminus of the
protein is not responsible for the interaction (Figure 6C).
Interestingly, the interaction of HA-MTS-nF2-GFP protein
with VDAC1 was also greatly reduced when compared to the
HA-nF2-GFP protein lacking the MTS (Figure 6D). It is
possible that forced localization of the nF2 to the inner
mitochondrial membrane may have prevented its interaction
with VDAC1 in the outer membrane.
The PB1-F2 Protein-Mediated Mitochondrial
Permeabilization Is Attenuated by ANT3 Blockers
We further investigated the role of the PTPC in PB1-F2-
induced mitochondrial permeabilization. We turned to the
known pore complex inhibitors: bongkrekic acid (BA), which
was shown to inhibit ANT3 [28], and cyclosporine A (CsA),
which binds to the mitochondrial matrix cyclophilin D and
also inhibits ANT3. Puriﬁed mouse liver mitochondria were
treated for 30 min with recombinant PB1-F2 protein in the
presence or absence of BA (Figure 7A). Incubation of
mitochondria with increasing doses of the PB1-F2 protein
resulted in dissipation of the mitochondrial membrane
potential as measured by JC-1 ﬂuorescence. This effect was
attenuated, although not completely inhibited, when the
mitochondria were preincubated with 50 lM BA (Figure 7A).
To conﬁrm the involvement of ANT3 in PB1-F2-induced
dissipation of the mitochondrial membrane potential in cells,
and to identify the domain of the protein responsible for this
permeabilization, we transfected HeLa cells with the PB1-F2-
GFP fusion constructs described in Figure 6 and stained the
cells with the mitochondrial membrane potential-sensitive
Mitotracker CMXRos Red dye. GFP protein was used as a
control. Consistent with previous reports [4,5], we found that
in the absence of other stimuli, the C-terminal domain of the
protein was more effective in dissipating the inner mem-
brane potential than the full-length protein (Figure 7B,
upper photomicrographs), as revealed by decreased Mito-
tracker Red staining in these cells. This is further consistent
with our ﬁndings that the C-terminal domain of the PB1-F2
protein is responsible for its interaction with ANT3 (Figure
6). Treatment of the HeLa cells expressing the PB1-F2-GFP
fusion construct with TNFa resulted in dissipation of the
membrane potential, further conﬁrming that the full-length
protein requires additional apoptotic stimuli for its effect
(Figure 7B). To conﬁrm that the PB1-F2-induced perme-
ability transition indeed proceeds in ANT3-dependent
manner, we performed the same experiment in the presence
of CsA, a known ANT3 inhibitor (Figure 7C). Treatment of
HeLa cells with CsA resulted in preservation of the
mitochondrial membrane potential in the cells expressing
the cF2-GFP and in the TNFa-treated cells expressing the
PB1-F2-GFP protein.
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To conﬁrm that the PB1-F2-mediated sensitization to
apoptosis proceeds in ANT3-dependent manner, we inves-
tigated whether BA, an ANT3 blocker, could inhibit this
effect. A549 cells were transfected with PB1-F2 for 24 h and
were subsequently treated with TNFa either in the presence
or absence of 50 lM BA. As can be seen from Figure 8A, BA
inhibited TNFa-induced apoptosis in these cells, as compared
to the untreated control. Overall, these results, along with the
interaction studies, suggest that the PTPC plays a role in PB1-
F2-induced mitochondrial permeabilization.
Discussion
Mitochondrial control of apoptosis is a critical gateway for
many cellular apoptotic pathways, whereby mitochondrial
permeabilization and release of mediator proteins represent
Figure 6. Identification of PB1-F2 Protein Domains Responsible for Interaction with ANT3 and VDAC1
(A) PB1-F2 N- and C-terminal domains were cloned separately as N-terminal HA- and C-terminal GFP fusion proteins as follows. (1) GFP control; (2) full-
length fusion protein (HA-PB1-F2-GFP); (3) C-terminal 38–87-amino acid domain fusion protein (HA-cF2-GFP); (4) N-terminal 1–37 amino acid domain
fusion protein (HA-nF2-GFP); (5) N-terminal domain fusion protein with cytochrome oxidase mitochondrial targeting sequence (HA-MTS-nF2-GFP); and
(6) control MTS-GFP fusion protein (HA-MTS-GFP).
(B) Localization of fusion proteins was determined in transfected HeLa cells (green, GFP-fusion protein; red, Mitotracker dye staining for mitochondria;
blue, DAPI nuclear stain).
(C and D) Interaction of fusion proteins with ANT3 and VDAC1 was determined by cotransfecting 293T cells with each fusion construct and a vector
encoding Flag-tagged ANT3 or VDAC1, respectively. Immunoprecipitation was performed with an anti-HA antibody, with subsequent immunoblotting
for Flag-tagged ANT3 or VDAC1.
DOI: 10.1371/journal.ppat.0010004.g006
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[29]. Permeabilization of mitochondria is thought to occur
through two proposed mechanisms, proceeding in either
permeability transition-dependent or -independent manner
[16,17]. The mechanisms are not mutually exclusive, and it is
generally believed that both play a role in the mitochondrial
induction of apoptosis, whereby the contribution of each
mechanism is dependent upon the apoptotic stimulus and/or
perhaps differential tissue-speciﬁc regulation [17].
Several viral and bacterial proteins have been shown to
induce or inhibit apoptosis through a direct effect on
different mitochondrial components [10,11]. Viruses of the
herpesvirus family evolved to regulate apoptosis by different
mechanisms, with some members encoding Bcl-2 family
homologs [30]. Porin proteins of Neisseria and the hepatitis
B virus X protein interact with VDAC [31–33]. Cytomegalo-
virus vMIA protein and HIV Vpr proteins affect the
Figure 7. PB1-F2 Protein Induces Mitochondrial Permeabilization in ANT3-Dependent Manner
(A) Recombinant PB1-F2 protein was incubated with 50 lg of purified mouse liver mitochondria in the presence or absence of 50 lM BA for 30 min. The
mitochondria were further processed for assessment of membrane potential by JC-1 fluorescence at 590 nm.
(B) PB1-F2 induces loss of mitochondrial membrane potential in transfected cells. HeLa cells were transfected with GFP fusion constructs of PB1-F2, and
12 h later were treated with 50 ng/ml TNFa for 8 h, where indicated. Cells were subsequently stained with Mitotracker CMXRos Red dye. Cells with
dissipated membrane potential are indicated by (*).
(C) The mitochondrial permeability transition inhibitor CsA inhibits PB1-F2-induced loss of mitochondrial membrane potential. HeLa cells in presence of
CsA were transfected and treated as in (B) and stained with Mitotracker dye.
DOI: 10.1371/journal.ppat.0010004.g007
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M11 protein of myxoma virus targets the peripheral
benzodiazepine receptor, another component of the pore
complex [36]. Still other viral proteins exert their effect on
the mitochondria through yet unidentiﬁed mechanisms
[10,11].
Knowing the role of inﬂuenza virus PB1-F2 protein in
apoptosis, we decided to elucidate its mechanism of action
and the role that the protein may play in viral infection. The
sensitivity to apoptosis of PB1-F2-expressing cells was greatly
enhanced in response to different cellular apoptotic stimuli,
such as DNA damage, anoikis, and signaling through death
receptors (see Figure 1). Similar ﬁndings were previously
reported for the hepatitis B virus X protein [37]. Since
proteins of the BH3 family such as Bid have been implicated
in both intrinsic and extrinsic apoptotic signaling [20,22,38],
we hypothesized that PB1-F2 may sensitize mitochondria to
proapoptotic effects of Bid. Indeed, treatment of puriﬁed
mitochondria with recombinant tBid in the presence of PB1-
F2 resulted in enhanced cytochrome c release (see Figure 4).
Furthermore, the proapoptotic effect of PB1-F2 on cells in
response to TNFa was blocked by Bcl-xL (see Figure 2), which
could occur through inhibition by Bcl-xL of either outer or
inner mitochondrial membrane permeabilization. Interest-
ingly, Bcl-xL overexpression did not inhibit PB1-F2-induced
disorganization of mitochondria (see Figure 3A). This
Figure 8. PB1-F2 Induces Apoptosis Acting through Components of the PTPC
(A) ANT3 blocker BA inhibits PB1-F2-mediated sensitization of cells to apoptosis. A549 cells were transfected with PB1-F2 for 20 h and then treated with
TNFa as indicated, either in the presence or absence of 50 lM BA. The cells were collected 8 h later and stained with M30 antibody to cleaved
cytokeratin.
(B) Proposed models of PB1-F2 action during infection. During early stages of the infection, PB1-F2 localizes to mitochondria, where it interacts with
ANT3 and VDAC and predisposes the mitochondria to permeability transition. Later in the infection, when more PB1-F2 is synthesized, and upon
induction of antiviral apoptotic signaling pathways, the mitochondria undergo the permeability transition, which results in the induction of apoptosis.
PB1-F2-induced mitochondrial permeabilization can proceed through three possible mechanisms, as indicated on the right graphic: (1) enhancement of
the pore complex formation through direct interaction with ANT3 and VDAC1; (2) independent permeabilization of the inner and outer mitochondrial
membranes with the help of ANT3 and VDAC1, respectively; and (3) direct permeabilization of the mitochondrial membranes.
DOI: 10.1371/journal.ppat.0010004.g008
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PB1-F2 may proceed through a different mechanism, possibly
through its interaction with tubulin (see Figure 5A).
Due to the unstable nature of the PB1-F2 protein and its
low expression levels within the cells, the studies described
above were performed in cell lines with good transfection
efﬁciencies, such as A549 and 293T cells. The major drawback
of this strategy is the transformed nature of these cells, which
may alter their apoptotic responses. In particular, as seen
from Figures 1 and 2, these cells are normally resistant to
proapoptotic effects of TNFa, suggesting that the survival/
proinﬂammatory pathways activated by TNFa exert a
dominant effect. Nevertheless, expression of the PB1-F2
protein shifted this balance toward the proapoptotic path-
ways in both cell lines.
We further evaluated the mechanism of PB1-F2-induced
mitochondrial permeabilization and determined that the
PB1-F2 protein directly induced cytochrome c release and
loss of the mitochondrial inner membrane potential in
puriﬁed mouse liver mitochondria (see Figure 4A and 4B),
suggesting that PB1-F2 may be acting in permeability
transition-dependent manner. This speculation was further
supported when proteins of the PTPC ANT3 and VDAC1
were identiﬁed in our PB1-F2 interaction screen.
To conﬁrm that PB1-F2-induced mitochondrial permeabi-
lization proceeds through the pore complex in an ANT3-
dependent manner, we used two known ANT3 blockers, BA
and CsA. These inhibitors attenuated the PB1-F2-induced
loss of the mitochondrial membrane potential both in
puriﬁed mitochondria (Figure 7A), and in live cells (Figure
7B). Furthermore, BA inhibited PB1-F2-mediated sensitiza-
tion of cells to apoptosis by TNFa (Figure 8A). This suggests
that, while similarly to the proteins of the Bcl-2 family, the
PB1-F2 protein may permeabilize membranes nonspeciﬁcally
[6,8,9], it induces a permeability transition in the inner
mitochondrial membrane in an ANT3-dependent manner.
ANT3 is localized to the inner mitochondrial membrane
and contributes to apoptosis induction by forming non-
speciﬁc pores that result in dissipation of the inner
mitochondrial membrane potential. Direct interaction of
ANT3 with several cellular and viral proteins (including the
HIV Vpr protein) has been shown to result in mitochondrial
permeabilization, leading to apoptosis [10,11]. The idea of the
importance of ANT3 involvement in apoptosis has recently
been challenged by the ﬁnding that the knockout of the
mouse homologs of ANT3 did not alter the induction of
apoptosis [39]. The results of that work nevertheless suggested
that ANT3 does have an essential role in regulating
permeability transition by modulating the sensitivity of the
pore complex to Ca
2þ activation and ANT ligands [39].
Similarly to the HIV Vpr, the inﬂuenza virus PB1-F2 protein
may act as a direct ligand to ANT3 [40].
Interaction of the PB1-F2 protein with both ANT3 and
VDAC1 was a surprising ﬁnding, since to our knowledge this
is the ﬁrst viral protein shown to interact with components of
the pore complex located in both inner and outer mitochon-
drial membranes. We further determined that, while inter-
action of PB1-F2 protein with ANT3 occurs through its C-
terminal domain (see Figure 6), interaction of PB1-F2 protein
with VDAC1 is mediated through both N- and C-terminal
regions. Overall, these data suggest a possible complex
formation between VDAC1, ANT3, and PB1-F2, whereby
PB1-F2 may bridge VDAC1 and ANT3, thus promoting
formation of the PTPC (see Figure 8B). Further experiments
will be needed to determine whether such a complex is
indeed formed within the cell. In this study, we did not
further identify the PB1-F2 protein residues responsible for
the interaction with ANT3 and VDAC1. In a previous study,
the inner mitochondrial membrane targeting signal was
mapped to the amphipathic helix within the C-terminal
region of the protein, consistent with our ﬁnding that the
PB1-F2 C-terminal region interacts with the inner membrane
ANT3 [4]. The amphipathic helix by itself was sufﬁcient to
dissipate the mitochondrial membrane potential, and muta-
tions within the amphipathic helix abolished the mitochon-
drial localization of the protein [4]. At this point, however, we
are unable to separate the mitochondrial-targeting and the
ANT3-binding domains of the PB1-F2 protein, since lack of
mitochondrial targeting also abolished PB1-F2-ANT3 inter-
action. In support of our ﬁndings, the N-terminal region of
the PB1-F2 protein targeted to mitochondria with a
heterologous inner mitochondrial membrane targeting se-
quence failed to interact with ANT3, conﬁrming the
speciﬁcity of the ANT3 interaction with the PB1-F2 C-
terminus.
The induction of permeability transition by PB1-F2 could
proceed through three possible mechanisms (Figure 8B).
Through its interaction with both ANT3 and VDAC1, PB1-F2
could potentially act as a bridge between the two proteins,
enhancing the formation of the pore complex (mechanism 1).
Alternatively, the protein could act separately at the inner
and outer mitochondrial membranes, in conjunction with
ANT3 and VDAC1, respectively (mechanism 2). The latter
model is supported by the evidence that PB1-F2 has been
shown to localize to both inner and outer mitochondrial
membranes and to directly induce membrane permeabiliza-
tion [3,6]. Recent studies also indicate that, similar to the
members of the Bcl-2 family, the PB1-F2 protein is capable of
forming multimeric complexes, which are probably respon-
sible for its membrane-permeabilizing activity [7]. Thus,
direct permeabilization of the mitochondrial membrane by
PB1-F2 protein complexes could account for the third
possible mechanism.
We chose to focus our studies on the VDAC1 and ANT3
proteins primarily because these proteins were identiﬁed in
our interaction screens, while other proteins localized to the
outer and inner mitochondrial membranes and the mito-
chondrial matrix (Tom20, COXIV, and Tim44) were ex-
cluded. In addition, these protein isoforms are speciﬁcally
known to be involved in the mitochondrial permeability
transition. We cannot, however, exclude the possibility that
the PB1-F2 protein may also interact with other isoforms of
ANT and VDAC. In particular, a recent study showed that the
VDAC2 isoform is implicated in suppression of mitochon-
drial apoptosis [41]. The fact that the ANT3-speciﬁc inhibitor
BA did not completely inhibit PB1-F2-induced inner mem-
brane permeabilization suggests that additional players may
be involved (Figure 7A). In addition, while the results of our
work propose the role of ANT3 in PB1-F2-induced perme-
abilization of the inner mitochondrial membrane, further
experiments are needed to determine the role of the VDAC1
protein and the function of the PB1-F2 protein in the outer
membrane. Our studies are currently limited by the lack of
availability of speciﬁc inhibitors against the VDAC1 protein.
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characterize the role of VDAC1 in PB1-F2-induced mito-
chondrial permeabilization.
Since the PB1-F2 protein is relatively short-lived and is
expressed mainly during the later stages of the infection cycle
[3], its proapoptotic effect most likely is not inhibitory to viral
replication. Based on our ﬁndings, we propose the following
model for the mode of PB1-F2 protein action within the cell
(Figure 8). Early in the infection cycle, PB1-F2 localizes to the
mitochondria, but does not induce a permeability transition
due to its low levels present within the cell. This allows for
maintenance of cell viability, which supports normal viral
replication. During later stages of infection, when enough
PB1-F2 protein is synthesized or when cellular mitochondrial
apoptotic signaling pathways are activated, the mitochondria
undergo a permeability transition.
While induction of apoptosis by inﬂuenza virus may at ﬁrst
seem counterintuitive to efﬁcient viral production, it has
been shown to be important in inﬂuenza viral replication.
First of all, inﬂuenza virus production is inhibited in stable
cell lines overexpressing Bcl-2, while activation of caspase 3
h a sb e e ns h o w nt ob ei m p o r t a n ti nr e p l i c a t i o na n d
propagation of inﬂuenza viruses [12–14,42]. In addition,
activation of the apoptotic cascade has been suggested to
play a role in processing of inﬂuenza viral proteins and
maturation of viral particles [43]. Moreover, we speculate that
sensitization of cells to death by TNFa rather than direct
induction of apoptosis by PB1-F2 could have several addi-
tional advantageous effects for the virus. TNFa has been
shown to exert a strong antiviral effect against inﬂuenza virus
[44], which is likely to proceed through nuclear factor kappa-
B- and c-Jun N-terminal kinase-dependent activation of
antiviral gene expression and secretion of antiviral cytokines,
such as type I interferon [45]. Sensitization of cells to the
proapoptotic effects of TNFa would minimize the antiviral
signaling to other cells. In support of this theory, induction of
apoptosis by inﬂuenza virus has been shown to limit the
release of proinﬂammatory cytokines [46]. Studies are
currently underway to analyze a possible differential effect
on cytokine induction by the wild-type and PB1-F2 mutant
viruses. Finally, as suggested by previous work, immune cells
seem to be more sensitive to induction of apoptosis by PB1-
F2, as indicated by the ﬁnding that PB1-F2-knockout
inﬂuenza virus induced less cell death than the wild-type
virus in infected human monocytes. This observation suggests
that the protein may play a role in down-regulation of the
host immune response to the infection [3]. Interestingly, the
ANT3 and VDAC1 proteins are expressed at different levels
in a variety of tissues and cell types, including lymphocytes
[47–50]. It is thus possible that these proteins may play a role
in the regulation of differential apoptotic responses in
different cell types following infection with inﬂuenza virus.
Further animal studies will be needed to evaluate the
function of the PB1-F2 protein in modulation of the immune
response and its overall role in the pathogenesis of inﬂuenza
virus infection.
Materials and Methods
Cell lines, antibodies, and reagents. 293T, A549, and HeLa cells
were obtained from ATCC and were maintained in DMEM culture
medium (Gibco, San Diego, California, United States) supplemented
with 10% fetal calf serum (Hyclone, South Logan, Utah, United
States), 100 U/ml of penicillin G sodium and 100 lg/ml of
streptomycin sulfate (Gibco). A549 cells stably overexpressing Bcl-
xL were generated by retroviral integration using the pLNCX2 vector
system with neomycin selection marker from Clontech (Palo Alto,
California, United States). Goat polyclonal antibodies to ANT3 and
VDAC1 were obtained from Santa Cruz Biotechnologies (Santa Cruz,
California, United States); monoclonal antibodies to Bcl-xL, cyto-
chrome c, Tom20, Tim44 and PARP were obtained from Pharmingen
(San Diego, California, United States); rabbit polyclonal antibody to
GFP was obtained from Clontech; M30 antibody against cleaved
cytokeratin was from Roche (Basel, Switzerland); and antibodies to
Flag and HA epitopes were obtained from Sigma (St. Louis, Missouri,
United States). Human anti-mitochondrial serum was obtained from
Immunovision (Springdale, Arizona, United States). Monoclonal anti-
PB1-F2 antibody (clone 26D3) was generated in mice immunized with
full-length recombinant PB1-F2 protein produced in E. coli. Poly-
clonal anti-PB1-F2 serum was generated in rabbits immunized with
full-length recombinant PB1-F2 protein. BA, cisplatin, and recombi-
nant tBid were obtained from Sigma; G418 and CsA were from
Calbiochem (San Diego, California, United States); Mitotracker Red
and JC-1 dyes, DAPI, monoclonal anti-COXIV antibody, and
secondary ﬂuorochrome-conjugated antibodies were obtained from
Molecular Probes (Eugene, Oregon, United States).
Constructs and cloning. The pCAGGS vector for the expression of
proteins under control of chicken b-actin promoter has been
described previously [51]. cDNAs for the full-length ANT3, VDAC1,
Bcl-xL, Bak, and Bax were obtained by reverse transcription with
oligo-dT primer from RNA obtained from A549 cells. PCR for each
gene was performed with gene-speciﬁc primers. An N-terminal HA or
Flag tag was introduced into each construct by PCR with 59 gene-
speciﬁc primers possessing the tag sequences. Each tagged gene was
introduced into the pCAGGS vector for mammalian expression and
into the pcDNA 3.1
þ vector (Invitrogen, Carlsbad, California, United
States) for in vitro transcription. The Bcl-xL gene was in addition
cloned into the pLNCX2 retroviral vector (Clontech) for stable
integration into A549 cells. The PB1-F2 gene was reverse-transcribed
and ampliﬁed with gene-speciﬁc primers by RT-PCR from viral RNA
of the inﬂuenza virus A/PuertoRico/8/34 strain. N-terminal HA and
Flag tags were introduced by PCR as outlined above. Tagged and
untagged constructs were cloned into the pCAGGS vector for
mammalian expression and the pGEX6P-1 vector (Amersham, Little
Chalfont, United Kingdom) for bacterial expression of the GST
fusion protein. The pCAGGS-GFP vector was generated by subclon-
ing the GFP gene from the pEGFP vector (Clontech). The HA-tagged
PB1-F2-GFP fusion construct was generated by insertion of the full-
length HA-tagged PB1-F2 gene into the pCAGGS-GFP vector. HA-
tagged constructs expressing either C- or N-terminally truncated
PB1-F2-GFP fusion proteins (HA-nF2-GFP and HA-cF2-GFP, respec-
tively) were generated by insertion of PCR-ampliﬁed C- or N-
terminal domains into the pCAGGS-GFP vector (see Figure 4). The
HA-MTS-nF2-GFP construct was generated by trimolecular ligation
of the HA-tagged cytochrome oxidase MTS sequence cloned from
A549 cells (sequence available from Clontech) and the N-terminal
domain of PB1-F2 using the pCAGGS-GFP vector. Sequences of each
generated construct were conﬁrmed by automated sequencing
performed at the Mount Sinai sequencing core facility. All primer
sequences are available upon request.
Recombinant protein puriﬁcation from E. coli. Competent BL-21
cells (Stratagene, La Jolla, California, United States) transformed with
pGEX6p-1 vector were cultured to an OD600 of 0.6 in 2XYT medium.
The cells were induced for 2 h at 37 8C with 1 mM IPTG, collected in
PBS, and frozen. Puriﬁcation of the GST fusion proteins was
performed using the GSH Sepharose resin (Amersham) according
to the manufacturer’s protocol. Puriﬁed protein was either eluted
with glutathione buffer (Amersham) as a GST fusion protein, or
cleaved from GST on the column with Prescission Protease
(Pharmacia, Uppsala, Sweden) and eluted with PBS.
Transfections for localization and apoptosis assays. A549 and HeLa
cells grown on coverslips were transfected in 24-well dishes with 1 lg
of vector of interest using Lipofectamine 2000 (Invitrogen) according
to the manufacturer’s instructions. After 24 h, the cells were ﬁxed with
5% formaldehyde in PBS and permeabilized with 1% Triton X-100.
Proteins of interest were visualized by indirect immunoﬂuorescence.
Cells were probed with speciﬁc primary antibody for 2 h at room
temperature,washed,andlabeledwithsecondaryantibodyconjugated
to a speciﬁc ﬂuorophore. Labeled cells were visualized by laser
scanning confocal microscopy (TCS-SP; Leica, Wetzlar, Germany)
with TCS-SP software for image capture. A Zeiss (Oberkochen,
Germany) Axiovert 200 microscope with Zeiss Axiovision software
was used for ﬂuorescence analysis of live cells. Protocols for assess-
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transfected for 24 h, trypsinized, and resuspended in serum-free
medium. Cellular morphology was analyzed for blebbing and
fragmentation under a phase-contrast microscope over the next hour.
Mitochondrial puriﬁcation and cytochrome c release assay. Freshly
isolated Balb/c mouse livers were homogenized and fractionated
according to the protocols described previously [52]. Puriﬁed
mitochondria were resuspended in MRM-S buffer (250 mM sucrose,
10 mM Hepes, 1 mM ATP, 5 mM succinate, 0.08 mM ADP, and 2 mM
K2HPO4 [pH 7.4]) to a ﬁnal concentration of 10 mg/ml protein. For
cytochrome c release assays, 50 lg of mitochondria (by total protein)
were incubated with recombinant PB1-F2 or tBid protein for 1 h at
30 8C in a total volume of 25 ll. After incubation, mitochondria were
pelleted and the supernatant was collected and analyzed for
cytochrome c release by immunoblotting for cytochrome c, while
the mitochondrial pellet was analyzed by Western blot for Tom20.
Determination of the mitochondrial membrane potential with JC-1
ﬂuorescence. Puriﬁed mitochondria (50 lg) were incubated with
proteins of interest for indicated times as described above. After
incubation, 1 ml of 200 nM JC-1 dye in MRM-S buffer was added to the
mitochondria and incubated at RT for 10 min. JC-1 ﬂuorescence was
measured in a Bio-Rad (Hercules, California, United States) ﬂuorom-
eter with the excitation ﬁlter of 490 nm and emission ﬁlter of 590 nm.
In vivo GST-fusion protein expression and GST pulldowns. For
identiﬁcation of cellular interactors, 293T cells in 15-cm dishes were
transfected with 15 lg of mammalian expression vector encoding
GST-fusion proteins of interest. Cells were collected 30 h post-
transfection and lysed in coimmunoprecipitation buffer (see below).
Lysates were incubated with glutathione beads for 4 h, and beads
were spun down and washed ten times in lysis buffer. Proteins were
eluted off the beads with glutathione elution buffer, as recommended
by the manufacturer’s instructions (Amersham).
Mass spectrometry and protein identiﬁcation. The fraction of the
eluted proteins was initially separated by SDS-PAGE (10%) and
analyzed by silver stain. For mass spectrometry analysis, the eluted
proteins were separated on the SDS-PAGE (10%) and visualized by
Coomassie blue staining. Bands of interest were cut out from the gel,
destained, reduced, alkylated, and digested with trypsin. Micro-HPLC
analysis of the tryptic peptides was conducted by using an LCQ
electrospray ionization ion trap mass spectrometer (ThermoFinni-
gan, Waltham, Massachusetts, United States) coupled to an online
MicroPro-HPLC system (Eldex Laboratories, Napa, California, United
States). Proteins were identiﬁed by using the peptide molecular
masses and their MS/MS fragment data to search the National Center
for Biotechnology Information nonredundant DNA and protein
sequence databases with the program KNEXUS (Genomic Solutions,
Ann Arbor, Michigan, United States).
Immunoprecipitations. For all coimmunoprecipitation experi-
ments, 293T cells in 35-mm dishes were transfected with 1 lgo f
each appropriate expression vector using Lipofectamine 2000 trans-
fection reagent (Invitrogen) according to the manufacturer’s proto-
col. Cells were collected 30 h post-transfection and lysed in the
coimmunoprecipitation buffer: 0.5% NP-40, 150 mM NaCl, 20 mM
Hepes (pH 7.4), 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 10% glycerol,
and Complete Protease Inhibitor Cocktail and PMSF (Roche).
Proteins were incubated at 4 8C overnight with 1 lgo ft h e
appropriate antibody, and protein complexes were precipitated with
protein G agarose beads (Roche) for 2 h. Beads were washed ﬁve times
in lysis buffer and resuspended in protein sample buffer. Proteins
were subsequently separated by 12% SDS-PAGE and detected by
Western blotting.
In vitro transcription/translation and GST pulldowns. Proteins
were in vitro transcribed and translated by use of a T7-coupled rabbit
reticulocyte system (Promega, Madison, Wisconsin, United States)
and
35S protein labeling mix (Perkin Elmer, Wellesley, California,
United States) according to the manufacturers’ protocols. For
binding experiments,
35S-labeled proteins were incubated with 5 lg
of either GST-PB1-F2 or GST with glutathione-Sepharose beads for 2
ha t48C in binding buffer (PBS with 0.25% NP-40 and 0.1% BSA) and
washed with binding buffer three times. The beads were then
resuspended in protein sample buffer, separated by 12% SDS-PAGE,
and analyzed by ﬂuorography for bound proteins. To visualize
35S-
labeled proteins by ﬂuorography, the gels were ﬁxed, incubated in
Amplify (Amersham), and dried before exposure to ﬁlm.
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